Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sonus Taxol rival gets orphan drug status
The product candidate has been granted orphan status for the treatment of non-superficial urothelial cancer, the most common form of which is bladder cancer. This designation adds to
The product candidate has been granted orphan status for the treatment of non-superficial urothelial cancer, the most common form of which is bladder cancer. This designation adds to
The clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of novel escalating dose and administration schedules of Taxotere in combination with
Davanat is a proprietary polysaccharide in a Carbosome formation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) that are unique to cancer cells. The
The tax claim principally relates to the allocation of taxes on profits for Glaxo Wellcome products between the US and other countries. GSK estimates that the interest owing
In the study, post-surgical use of Femara (letrozole tablets) in postmenopausal women with hormone receptor-positive early breast cancer demonstrated a significant 19% reduction in risk of relapse, reducing
No current vaccine is available to prevent hookworm disease, which is one of the most common chronic infections of humans with an estimated 740 million cases in areas
The successful application for fast track status was based on data derived from a phase Ib/IIa study, conducted in two Australian hospitals, in which men with late stage
The investigational PYY3-36 nasal spray is designed to deliver the natural, appetite-regulating hormone PYY directly to the bloodstream. Nastech has completed three phase I clinical trials, each designed
Procyon said that, in order to maximize shareholder value in the short to medium term, it would now shift its focus from being an early-stage research company to
The pivotal phase III trial is a double blind, placebo controlled, multicenter study. Patients with high grade prostatic intraepithelial neoplasia (PIN), the precancerous lesion in prostate cancer, will